Antibodies targeting immune checkpoint (e.g., PD-1/PD-L1, CTLA-4) have become the first-line treatment for multiple malignancies such as head and neck squamous cell carcinoma (HNSCC)2. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.